Cerevel Therapeutics Holdings, Inc. ( NASDAQ:CERE – Get Free Report ) has been assigned an average recommendation of 'Moderate Buy' from the twelve research firms that are currently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $34.80. Several equities research analysts have recently issued reports on the company.

https://www.dailypolitical.com/2023/07/16/cerevel-therapeutics-holdings-inc-nasdaqcere-receives-34-80-average-price-target-from-analysts.html

#dailypolitical